DUBLIN--(BUSINESS WIRE)--The "PharmSource - Cell Therapy Market Opportunity for CMOs - 2018 Edition" report has been added to ResearchAndMarkets.com's offering.
This report will explore whether the bio/pharma industry is adequately prepared for future cell therapy developments and whether pharma companies and CDMOs are making appropriate investments in the capacity and technology to support the coming opportunity.
Cell therapies represent an exciting and complex new treatment type, with the potential to treat an enormous range of indications, in some cases offering the possibility of a disease cure with a single treatment. Of the current clinical pipeline, it is anticipate that approximately 80 therapies will be approved by the FDA.
Cell therapy manufacturing is in its infancy, using time-, space-, and labor-intensive techniques that are appropriate for current volume needs, mostly driven by clinical trials. However, these methods will no longer be practicable for the scaled-up commercial cell therapy requirements of the near future. Given the necessary time-lag for building capacity, the industry must immediately begin to address next-generation technologies, driven by automation.
Portions of the CDMO industry are investing in greater capacity to support the future cell therapy pipeline. And small- and medium-sized cell therapy developers, which represent a sizeable portion of the pipeline, will need to rely on contract manufacturing, at least at first, as initial outlay for these complex technologies will be very high.
This report seeks to achieve the following objectives:
- To describe and evaluate the cell therapy market opportunity;
- To describe and address the adequacy of the network of CDMOs that manufacture for the cell therapy market, both clinical and commercial;
- To assess the outlook for buyers and sellers of contract manufacturing services for cell therapies, including the supply/demand balance.
Key Topics Covered
1. Executive Summary
2. Introduction
3. Commercial Cell Therapy Experience
4. Cell Therapy Pipeline
5. Next-Generation Technologies
6. Approvals Outlook
7. Cell Therapy Supply Chain
8. Demand Models
9. What it Means
10. Notes on Methodology
Companies Featured
- Cellectis
- China PLA General Hospital
- GSK
- 3P Biopharmaceuticals
- Abzena
- Anemocyte SRL
- Autolus
- Bio Elpida
- Bioinova sro
- Brammer Bio
- CCRM
- Celgene
- Cell and Gene Therapy Catapult
- CellforCure
- Cellin Technologies LLC
- Cellular Therapeutics Ltd.
- Fraunhofer Group
- GE Healthcare
- Gencure
- Gilead Sciences Inc.
- Histocell SL
- Hitachi Chemical Co Ltd
- Lonza Group
- MaSThercell
- NHS Blood and Transplant
- Nikon Corporation
- Novartis International AG
- Novartis Pharmaceuticals Corp.
- Organogenesis Inc.
- Oxford Biomedica
- Pfizer
- Provia Laboratories LLC
- WuXi AppTec
- Yposkesi
-
and many more...
For more information about this report visit https://www.researchandmarkets.com/research/2bnjxq/pharmsource?w=4
